Concord Biotech Approves 1:1 Bonus Issue; Authorised Share Capital to Double
Concord Biotech Limited (NSE: CONCORDBIO, BSE: 543960) has approved a 1:1 bonus share issue, subject to shareholder approval, according to the outcome of its Board meeting held on September 23, 2026.
Under the proposed bonus issue, shareholders will receive one bonus equity share of ₹1 each for every one existing fully paid-up equity share of ₹1 each held on the record date. The record date will be decided by the Board at a later stage.
The company said the bonus shares will be issued by capitalising its share premium account.
Concord Biotech 1:1 Bonus Issue Details
Concord Biotech plans to issue approximately 10.46 crore bonus equity shares of ₹1 each, representing a total nominal value of ₹10.46 crore.
The bonus issue will be funded from the company’s share premium account. As of March 31, 2026, Concord Biotech had a share premium balance of approximately ₹81.97 crore, while ₹10.46 crore will be required for the proposed bonus issue.
The company has confirmed that the relevant financial figures are audited.
Pre- and Post-Bonus Share Capital
Before the bonus issue, Concord Biotech’s paid-up equity share capital stands at approximately ₹10.46 crore, comprising 10.46 crore equity shares of ₹1 each.
After the proposed 1:1 bonus issue, the paid-up share capital would increase to approximately ₹20.92 crore, comprising 20.92 crore equity shares of ₹1 each.
| Particular | Details |
|---|---|
| Bonus ratio | 1:1 |
| Existing shares | 10,46,16,204 |
| Bonus shares proposed | 10,46,16,204 |
| Post-bonus shares | 20,92,32,408 |
| Face value | ₹1 per share |
| Amount capitalised | ₹10.46 crore |
| Source | Share premium account |
| Record date | To be announced |
| Shareholder approval | Required |
Authorised Share Capital to Double
Along with the bonus issue, the Board approved a proposal to increase the company’s authorised share capital from ₹11 crore to ₹22 crore.
The authorised capital will increase from:
₹11 crore → ₹22 crore
This will involve increasing the number of authorised equity shares from 11 crore to 22 crore shares, with each share having a face value of ₹1.
The company’s Memorandum of Association will also be amended accordingly, subject to shareholder approval.
Bonus Shares Expected by November 2026
Concord Biotech said the proposed bonus shares are expected to be credited or dispatched within two months from the date of the Board meeting approving the bonus issue, which means the company has indicated a timeline of on or before November 22, 2026.
However, the actual process remains subject to the required shareholder approval and completion of applicable formalities.
What the 1:1 Bonus Issue Means
A 1:1 bonus issue means that an eligible shareholder holding 100 Concord Biotech shares on the record date would receive 100 additional bonus shares, subject to the applicable conditions.
The bonus issue does not by itself increase the economic value of an investor’s holding at the time of the adjustment. The number of shares doubles while the market price typically adjusts proportionately, all else being equal.
The key significance for investors is therefore the company’s decision to increase the number of outstanding shares and its authorised share capital, rather than treating the bonus issue itself as an increase in shareholder wealth.
Why Concord Biotech’s Announcement Matters
The announcement has two major components:
- 1:1 bonus issue through capitalisation of the share premium account.
- Doubling of authorised share capital from ₹11 crore to ₹22 crore.
The company has not announced the record date yet. Investors will need to monitor subsequent exchange filings for the record date and details of the shareholder approval process.
Concord Biotech Bonus Issue: Key Dates
Board approval: September 23, 2026
Bonus ratio: 1:1
Record date: To be announced
Shareholder approval: Required
Expected bonus credit timeline: By November 22, 2026, subject to completion of applicable formalities
Bottom Line
Concord Biotech has approved a 1:1 bonus issue, under which approximately 10.46 crore new equity shares will be issued to eligible shareholders. The company will capitalise ₹10.46 crore from its share premium account for the issue.
At the same time, Concord Biotech plans to double its authorised share capital from ₹11 crore to ₹22 crore, subject to shareholder approval.
Investors should watch for the company’s next announcement regarding the record date and shareholder approval.
Source: Concord Biotech Limited, Board Meeting Outcome dated September 23, 2026.
